Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM57CS)

• Drug Name: Drug 2849330 Drug Info
• Synonyms: 2849330

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMM57CS

Molecule-Related Drug Atlas

Drug(s) Targeting Erbb3 tyrosine kinase receptor (Erbb-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[3]
MEHD-7945A	DMHOF7T	Colorectal cancer	2B91.Z	Phase 2	[4]
Seribantumab	DMYT470	Colorectal cancer	2B91.Z	Phase 2	[5]
CDX-3379	DM5GKYD	Squamous cell carcinoma	2B60-2D01	Phase 2	[5]
MM-121	DMDJRU1	Breast cancer	2C60-2C65	Phase 2	[6]
Elisidepsin	DMB38KH	Psoriasis vulgaris	EA90	Phase 2	[7]
Zenocutuzumab	DM1FLHH	Pancreatic cancer	2C10	Phase 2	[8]
Sym013	DMZM6I2	Epithelial ovarian cancer	2B5D	Phase 1/2	[9]
Zenocutuzomab	DMMQGPE	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[10]
LJM716	DMGTB5N	Breast cancer	2C60-2C65	Phase 1/2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb3 tyrosine kinase receptor (Erbb-3)	TTDC8N2	ERBB3_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT01966445) Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors. U.S. National Institutes of Health.
• [2] National Cancer Institute Drug Dictionary (drug id 754219).
• [3] MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
• [4] Company report (Biooncology)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Company report (Merrimack)
• [7] Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64.
• [8] Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 May 2;12(5):1233-1247.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of Merus.
• [11] An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35.